Please use this identifier to cite or link to this item: http://223.31.159.10:8080/jspui/handle/123456789/1716
Title: Identification of NRPS and type II PKS biosynthetic gene cluster (s) encoding decaplanin and kigamicin from Amycolatopsis regifaucium DSM 45072T
Authors: Bisht, Niyati
Mayilraj, Shanmugam
Kumar, Shailesh
Kaur, Navjot
Keywords: Amycolatopsis regifaucium DSM 45072T
Antibiotics
Amycolatopsis decaplanina DSM 44594T
Biosynthetic gene clusters (BGCs)
Issue Date: 2025
Publisher: Oxford University Press
Citation: FEMS Microbiology Letters, 372: fnaf049
Abstract: Amycolatopsis regifaucium, a Gram-positive actinomycete, is a prolific source of biologically active compounds, including polyphenol antibiotics like kigamicins. This study presents the draft genome of Amycolatopsis regifaucium DSM 45072T (= GY080T), which spans 8.28 Mbp and is assembled into 62 contigs, with annotation revealing 312 subsystems, 7,966 coding genes, and 52 RNAs, with a GC content of 68.5 mol%. We found a significant genomic diversity within the genus, revealing variations in core and accessory genomic elements across species. Multiple biosynthetic gene clusters (BGCs) have been identified, including a previously unidentified glycopeptide antibiotic (GPA) gene cluster and a type II polyketide synthase (PKS) gene cluster, highlighting the organism's metabolic versatility and potential for the biosynthesis of novel natural products. Our analysis confirmed the production of decaplanin, an antibiotic previously attributed to Amycolatopsis decaplanina DSM 44594T. Correspondingly, the gene cluster responsible for decaplanin biosynthesis is identified in A. regifaucium DSM 45072T and A. decaplanina DSM 44594T. Additionally, a putative type II PKS gene cluster is predicted within the glycopeptide antibiotic-producing clade (Cluster A) of the genus Amycolatopsis. Genomics insights from Amycolatopsis regifaucium DSM 45072T represent it as a promising genetic resource with significant implications for biotechnological and pharmaceutical innovation, particularly in discovering and developing novel antimicrobial agents.
Description: Accepted date: 19 May 2025
URI: https://academic.oup.com/femsle/advance-article/doi/10.1093/femsle/fnaf049/8137895?login=true
http://223.31.159.10:8080/jspui/handle/123456789/1716
ISSN: 1574-6968
0378-1097
Appears in Collections:Institutional Publications

Files in This Item:
File Description SizeFormat 
Kumar Shai_2025_4.pdf
  Restricted Access
1.51 MBAdobe PDFView/Open Request a copy


Items in IR@NIPGR are protected by copyright, with all rights reserved, unless otherwise indicated.